Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 233309 4200 Medical Devices & Consumables 377 187 Pages 4.7 (49)
                                          

Industry Growth Insights published a new data on “Cardiac Biomarkers Testing Market”. The research report is titled “Cardiac Biomarkers Testing Market research by Types (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others), By Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others), By Players/Companies Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, ROCHE, Siemens AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Tosoh Corporation”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Cardiac Biomarkers Testing Market Research Report

By Type

Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others

By Application

Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others

By Companies

Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, ROCHE, Siemens AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Tosoh Corporation

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

187

Number of Tables & Figures

131

Customization Available

Yes, the report can be customized as per your need.


Global Cardiac Biomarkers Testing Industry Outlook


Global Cardiac Biomarkers Testing Market Report Segments:

The global Cardiac Biomarkers Testing market is segmented on the basis of:

Types

Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia-modified Albumin (IMA), Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Abbott Laboratories
  2. Becton, Dickinson and Company
  3. BioMerieux
  4. Bio-Rad Laboratories, Inc.
  5. Danaher Corporation
  6. ROCHE
  7. Siemens AG
  8. Thermo Fisher Scientific, Inc.
  9. PerkinElmer Inc.
  10. Tosoh Corporation

Global Cardiac Biomarkers Testing Market Overview


Highlights of The Cardiac Biomarkers Testing Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Myocardial Muscle Creatine Kinase (CK-MB)
    2. Troponins (T and I)
    3. Myoglobin
    4. Brain Natriuretic Peptide (BNPs) or NT-proBNP
    5. Ischemia-modified Albumin (IMA)
    6. Others
  1. By Application:

    1. Myocardial Infarction
    2. Congestive Heart Failure
    3. Acute Coronary Syndrome
    4. Atherosclerosis
    5. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Cardiac Biomarkers Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Cardiac Biomarkers Testing Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Cardiac biomarkers testing is a type of medical test that measures the levels of specific cardiac proteins in the blood. These proteins can indicate whether a person has heart disease, and may help doctors diagnose and treat the condition.

Some of the key players operating in the cardiac biomarkers testing market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories, Inc., Danaher Corporation, ROCHE, Siemens AG, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Tosoh Corporation.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cardiac Biomarkers Testing Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Cardiac Biomarkers Testing Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Cardiac Biomarkers Testing Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Cardiac Biomarkers Testing Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Cardiac Biomarkers Testing Market Size & Forecast, 2018-2028       4.5.1 Cardiac Biomarkers Testing Market Size and Y-o-Y Growth       4.5.2 Cardiac Biomarkers Testing Market Absolute $ Opportunity

Chapter 5 Global Cardiac Biomarkers Testing Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2 Cardiac Biomarkers Testing Market Size Forecast by Type
      5.2.1 Myocardial Muscle Creatine Kinase (CK-MB)
      5.2.2 Troponins (T and I)
      5.2.3 Myoglobin
      5.2.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
      5.2.5 Ischemia-modified Albumin (IMA)
      5.2.6 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global Cardiac Biomarkers Testing Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2 Cardiac Biomarkers Testing Market Size Forecast by Applications
      6.2.1 Myocardial Infarction
      6.2.2 Congestive Heart Failure
      6.2.3 Acute Coronary Syndrome
      6.2.4 Atherosclerosis
      6.2.5 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Cardiac Biomarkers Testing Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Cardiac Biomarkers Testing Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America Cardiac Biomarkers Testing Analysis and Forecast
   9.1 Introduction
   9.2 North America Cardiac Biomarkers Testing Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America Cardiac Biomarkers Testing Market Size Forecast by Type
      9.6.1 Myocardial Muscle Creatine Kinase (CK-MB)
      9.6.2 Troponins (T and I)
      9.6.3 Myoglobin
      9.6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
      9.6.5 Ischemia-modified Albumin (IMA)
      9.6.6 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America Cardiac Biomarkers Testing Market Size Forecast by Applications
      9.10.1 Myocardial Infarction
      9.10.2 Congestive Heart Failure
      9.10.3 Acute Coronary Syndrome
      9.10.4 Atherosclerosis
      9.10.5 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe Cardiac Biomarkers Testing Analysis and Forecast
   10.1 Introduction
   10.2 Europe Cardiac Biomarkers Testing Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe Cardiac Biomarkers Testing Market Size Forecast by Type
      10.6.1 Myocardial Muscle Creatine Kinase (CK-MB)
      10.6.2 Troponins (T and I)
      10.6.3 Myoglobin
      10.6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
      10.6.5 Ischemia-modified Albumin (IMA)
      10.6.6 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe Cardiac Biomarkers Testing Market Size Forecast by Applications
      10.10.1 Myocardial Infarction
      10.10.2 Congestive Heart Failure
      10.10.3 Acute Coronary Syndrome
      10.10.4 Atherosclerosis
      10.10.5 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific Cardiac Biomarkers Testing Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific Cardiac Biomarkers Testing Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific Cardiac Biomarkers Testing Market Size Forecast by Type
      11.6.1 Myocardial Muscle Creatine Kinase (CK-MB)
      11.6.2 Troponins (T and I)
      11.6.3 Myoglobin
      11.6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
      11.6.5 Ischemia-modified Albumin (IMA)
      11.6.6 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific Cardiac Biomarkers Testing Market Size Forecast by Applications
      11.10.1 Myocardial Infarction
      11.10.2 Congestive Heart Failure
      11.10.3 Acute Coronary Syndrome
      11.10.4 Atherosclerosis
      11.10.5 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America Cardiac Biomarkers Testing Analysis and Forecast
   12.1 Introduction
   12.2 Latin America Cardiac Biomarkers Testing Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America Cardiac Biomarkers Testing Market Size Forecast by Type
      12.6.1 Myocardial Muscle Creatine Kinase (CK-MB)
      12.6.2 Troponins (T and I)
      12.6.3 Myoglobin
      12.6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
      12.6.5 Ischemia-modified Albumin (IMA)
      12.6.6 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America Cardiac Biomarkers Testing Market Size Forecast by Applications
      12.10.1 Myocardial Infarction
      12.10.2 Congestive Heart Failure
      12.10.3 Acute Coronary Syndrome
      12.10.4 Atherosclerosis
      12.10.5 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA) Cardiac Biomarkers Testing Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA) Cardiac Biomarkers Testing Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA) Cardiac Biomarkers Testing Market Size Forecast by Type
      13.6.1 Myocardial Muscle Creatine Kinase (CK-MB)
      13.6.2 Troponins (T and I)
      13.6.3 Myoglobin
      13.6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
      13.6.5 Ischemia-modified Albumin (IMA)
      13.6.6 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA) Cardiac Biomarkers Testing Market Size Forecast by Applications
      13.10.1 Myocardial Infarction
      13.10.2 Congestive Heart Failure
      13.10.3 Acute Coronary Syndrome
      13.10.4 Atherosclerosis
      13.10.5 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Cardiac Biomarkers Testing Market: Competitive Dashboard
   14.2 Global Cardiac Biomarkers Testing Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Abbott Laboratories
      14.3.2 Becton, Dickinson and Company
      14.3.3 BioMerieux
      14.3.4 Bio-Rad Laboratories, Inc.
      14.3.5 Danaher Corporation
      14.3.6 ROCHE
      14.3.7 Siemens AG
      14.3.8 Thermo Fisher Scientific, Inc.
      14.3.9 PerkinElmer Inc.
      14.3.10 Tosoh Corporation

Our Trusted Clients

Contact Us